Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma
Open Access
- 4 January 2024
- journal article
- research article
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 56 (1) , 177-191
Abstract
Dysregulation of wild-type p53 turnover is a key cause of hepatocellular carcinoma (HCC), yet its mechanism remains poorly understood. Here, we report that WD repeat and SOCS box containing protein 2 (WSB2), an E3 ubiquitin ligase, is an independent adverse prognostic factor in HCC patients. WSB2 drives HCC tumorigenesis and lung metastasis in vitro and in vivo. Mechanistically, WSB2 is a new p53 destabilizer that promotes K48-linked p53 polyubiquitination at the Lys291 and Lys292 sites in HCC cells, leading to p53 proteasomal degradation. Degradation of p53 causes IGFBP3-dependent AKT/mTOR signaling activation. Furthermore, WSB2 was found to bind to the p53 tetramerization domain via its SOCS box domain. Targeting mTOR with everolimus, an oral drug, significantly blocked WSB2-triggered HCC tumorigenesis and metastasis in vivo. In clinical samples, high expression of WSB2 was associated with low wild-type p53 expression and high p-mTOR expression. These findings demonstrate that WSB2 is overexpressed and degrades wild-type p53 and then activates the IGFBP3-AKT/mTOR axis, leading to HCC tumorigenesis and lung metastasis, which indicates that targeting mTOR could be a new therapeutic strategy for HCC patients with high WSB2 expression and wild-type p53.Keywords
This publication has 51 references indexed in Scilit:
- RETRACTED ARTICLE: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cellsMolecular Cancer, 2013
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Phase 1/2 study of everolimus in advanced hepatocellular carcinomaCancer, 2011
- p53 post-translational modification: deregulated in tumorigenesisTrends in Molecular Medicine, 2010
- EverolimusClinical Cancer Research, 2010
- p53 Regulation of the IGF-1/AKT/mTOR Pathways and the Endosomal CompartmentCold Spring Harbor Perspectives in Biology, 2009
- The first 30 years of p53: growing ever more complexNature Reviews Cancer, 2009
- Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosisThe EMBO Journal, 2009
- Cytoplasmic functions of the tumour suppressor p53Nature, 2009
- Regulation of p53 stability by Mdm2Nature, 1997